Clinical Trials Directory

Trials / Completed

CompletedNCT03439423

Control Post Endovascular Treatment of Aortic Aneurisms Through Magnetic Resonance and Ultrasound (SAFEVAR)

Controllo Dopo Trattamento Endovascolare di Aneurismi Aortici Mediante Risonanza Magnetica Senza Mezzo di Contrasto ed Ecografia Con Color-doppler: Accuratezza Diagnostica, Analisi Costo-efficacia e Impatto Sul Management Del Paziente

Status
Completed
Phase
Study type
Observational
Enrollment
250 (estimated)
Sponsor
IRCCS Policlinico S. Donato · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aims of this study are to verify non-inferiority of magnetic resonance (MR) without contrast agent associated to color-Doppler ultrasound for the diagnosis of endoleaks after endovascular aortic repair (EVAR), to evaluate both the economical and biological cost-effectiveness of such diagnostic algorithm as an alternative to computed tomography (CT) with contrast agent, and to analyze its impact on both patients work-flow and infrastructure logistics

Detailed description

In this prospective observational study, 250 patients who underwent EVAR will be studied. They will be enrolled after referral for a CT with contrast agent at IRCCS Policlinico San Donato or at ASST Santi Paolo e Carlo. Those with absolute contraindications to RM will be excluded. All enrolled subjects will undergo MR with contrast agent and color-Doppler ultrasound after CT. Before and after each examination, they will be submitted a questionnaire to evaluate their perception towards the former, and both costs and exposure deriving from such examinations will be evaluated along with patients' responses. Moreover, both CT and MR along with color-Doppler ultrasound will be analyzed with regards to human resources management, operational management, patients' clinical workflow and organization. All CT examinations will be independently evaluated by two radiologists with 4- and 8-year expertise in thoracic or abdominal CT. Results obtained from CT examinations will be used as a reference standard using the "worst case scenario" method: if either reader reported endoleak, the CT will be considered positive. The more experienced reader will anonymously and randomly repeat CT evaluation after 1 month. For CMR examinations, a 15-minute protocol will be used on a 1.5-T device. The following sequences will be performed: * steady state free-precession (true-FISP) * half-Fourier single shot spin-echo (HASTE) All examinations will be independently and blindly evaluated by the same two radiologists as CT examinations, and they will be considered positive if areas (even smaller than 5 mm) of alterate signal in comparison to surrounding muscle in the same slice are present inside the aneurismatic sac. The more experienced reader will anonymously and randomly repeat CT evaluation after 1 month. Color-Doppler ultrasound will be performed with a 1-5 MHz probe, by a radiologist with 7-year expertise in aortic ultrasound, blinded to MR and CT results. Ultrasound images will be evaluated both directly and through spectral flow study. The sample size was calculated assuming an alpha error of 5%, 90% power and 10% endoleak prevalence. In order to prove a negative predictive value of MR without contrast agent and color-Doppler ultrasound not inferior to 90%, 250 patients should be enrolled.

Conditions

Interventions

TypeNameDescription
RADIATIONCT with contrast agent
DIAGNOSTIC_TESTMR without contrast agenton 1.5-T unit, with the following sequences: * steady-state free-precession (true-FISP) * half-Fourier single shot spin-echo (HASTE)
DIAGNOSTIC_TESTColor-Doppler Ultrasound
OTHERQuestionnaireregarding their perception of examinations

Timeline

Start date
2016-03-09
Primary completion
2022-09-12
Completion
2022-09-12
First posted
2018-02-20
Last updated
2022-09-13

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT03439423. Inclusion in this directory is not an endorsement.

Control Post Endovascular Treatment of Aortic Aneurisms Through Magnetic Resonance and Ultrasound (SAFEVAR) (NCT03439423) · Clinical Trials Directory